Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2023-03-01 Regulatory Filings
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an announcement of interim clinical trial data from a Phase 2a study, including efficacy and safety results. It does not contain comprehensive financial statements or detailed financial analysis. The document length is 4133 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is an earnings release, annual report, or other detailed financial filing. The nature of the content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement of clinical trial results and other material events without detailed financial data or formal report structure.
2023-03-01 English
SC 13G/A
Major Shareholding Notification
2023-02-14 English
SCHEDULE 13G/A, AMENDMENT #2
Major Shareholding Notification
2023-02-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 14, 2023. It announces that the company, Cidara Therapeutics, regained compliance with Nasdaq's minimum bid price requirement. The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The length is 3095 characters, which is relatively short and primarily serves as an announcement of an event rather than a full report. According to the rules, such filings that announce events or updates without detailed financial data or full reports are best classified as Regulatory Filings (RNS).
2023-02-14 English
FORM 4
Director's Dealing
2023-01-27 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 15, 2022, by Cidara Therapeutics, Inc. The content focuses on the submission of matters to a vote of security holders at a Special Meeting, including detailed voting results on proposals such as a reverse stock split and adjournment. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is under 5,000 characters and contains detailed voting results, not just an announcement of a report. Therefore, the correct classification is DVA.
2022-12-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.